Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
Author:
Funder
UCB Pharma
Amgen Inc
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Link
https://link.springer.com/content/pdf/10.1007/s00198-022-06544-2.pdf
Reference25 articles.
1. Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937–948. https://doi.org/10.2147/TCRM.S72456
2. Laurs-van Geel TACM, Center JR, Geusens PP, Dinant G-J, Eisman JA (2010) Clinical fractures cluster in time after initial fracture. Maturitas 67:339–342. https://doi.org/10.1016/j.maturitas.2010.09.002
3. Bouxsein ML, Eastell R, Lui L-Y et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632–642. https://doi.org/10.1002/jbmr.3641
4. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26. https://doi.org/10.1002/jbmr.173
5. Black DM, Bauer DC, Vittinghoff E et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672–682. https://doi.org/10.1016/S2213-8587(20)30159-5
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. What’s New in Osteoporosis: Emphasis on the Aging Athlete;Journal of Bone and Joint Surgery;2024-07-25
2. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials;Journal of Bone and Mineral Metabolism;2024-07-08
3. Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury;JBMR Plus;2024-05-31
4. Diagnosis and treatment of osteoporosis: a paradigm shift;FOCUS. Endocrinology;2024-05-07
5. Age-related disease: Bones;Aging;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3